Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.20
$0.03(2.20%)
At close: 4:00 PM EDT
$1.20
$0.03(2.20%)
Day’s Range― - ―
52-Week Range$0.96 - $2.73
Previous CloseN/A
Volume7.02K
Average Volume (3M)43.54K
Market Cap
$10.19M
Enterprise Value$9.22
Total Cash (Recent Filing)$21.94M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume51,779
30 Day Avg. Volume43,544
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Compelling Glioblastoma Clinical DataA 97% improvement in median PFS versus standard of care is a structurally significant clinical signal for a difficult indication. Durable positive survival data can support regulatory engagement, accelerate pathway discussions, increase partner interest, and materially de-risk the GBM program over a 2–6 month horizon and beyond.
Platform With Multiple ProgramsA platform approach (γδ T‑cell engager and cell therapy programs) with multiple IND-stage and preclinical candidates provides diversification and multiple value-creation paths. This modular pipeline increases long-term probability of a successful asset and makes the company a more attractive partner for collaborations.
Improving Cash Burn TrajectoryOperating and free cash flow trends have meaningfully improved from heavier historical burn, reflecting better cost control and operational discipline. Sustained reduction in cash burn extends runway, lowers near-term financing pressure, and improves the company's ability to advance key trials over the medium term.
Bears Say
No Commercial RevenueThe company lacks product sales and is a pure development-stage biotech; without recurring commercial revenue, long-term viability depends on clinical success, partnerships, or financing. This makes operational plans and R&D progress highly contingent on positive trial outcomes and external funding.
Sustained Negative Free Cash FlowPersistently negative operating and free cash flow (~-$14.5M TTM) means the business cannot self-fund development and must raise capital to progress studies. This structural cash deficit pressures management to prioritize resource allocation and increases dilution risk over successive funding rounds.
Reliance On Equity Financing (ATM Program)The use of at‑the‑market equity facilities as a primary financing tool signals structural dependence on public equity. Over time this creates dilution risk, ties funding ability to market conditions, and can limit strategic optionality if capital markets are strained when development milestones require funding.
IN8bio News
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $0.96 and its highest was $2.73 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $10.19M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.618 by $0.358.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.34.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.618. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(316.67% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―
Ownership Overview
5.04% Insiders
4.50% Mutual Funds
25.63% Other Institutional Investors
63.93% Public Companies and
Individual Investors